ACTRN12612000333819RecruitingPhase 2
An open-label, single-arm, multicentre trial to determine safety and efficacy of eculizumab in the prevention of antibody mediated rejection (AMR) in sensitized recipients of a kidney transplant from a deceased donor.
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Sponsor
- Alexion Pharmaceuticals Inc
- Enrollment
- 40
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
- Allocation
- Non-randomised trial
- Primary Purpose
- Prevention
- Masking
- Open (masking not used)
Eligibility Criteria
- Ages
- 18 Years to o limit (—)
- Sex
- All
Inclusion Criteria
- •Patients with stage V chronic kidney disease who will receive a kidney transplant from a deceased donor to whom they are sensitized; able to understand the informed consent form and willing to complly with study procedures.
Exclusion Criteria
- •Prior treatment with eculizumab; blood type incompatible with donor; any medical condition that, in the opinion of the investigator, might interfere with the patient's participation in the study, poses an added risk for the patient, or confounds the assessment of the patient.
Investigators
Similar Trials
Completed
Phase 3
A randomized, open label, multicentre trial to define the most effective haemoglobin concentration to start erythropoietin beta (neoRecormon) therapy in anaemic subjects with lymphoproliferative malignancy receiving chemotherapy *REPOS Study*anemiaNL-OMON34234HagaZiekenhuis150
Completed
Phase 3
Effect of oral clear fluid comprising 12% carbohydrate on post-anesthesia recovery profile in childreCTRI/2017/10/010110Archana A Bharadwaj101
Completed
Phase 3
Single arm trial with afatinib to assess its safety in patients with non-small cell lung cancer(NSCLC)harboring EGFR mutation(s)CTRI/2014/08/004907Boehringer Ingelheim Hongkong50
Active, not recruiting
Phase 1
Study of Efficacy and Safety of Twice Daily Oral iptacopan in Adult PNH Patients who are naïve to complement inhibitor therapyParoxysmal Nocturnal Hemoglobinuria (PNH)MedDRA version: 21.1Level: PTClassification code 10034042Term: Paroxysmal nocturnal haemoglobinuriaSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2020-003172-41-CZovartis Pharma AG40
Active, not recruiting
Phase 1
Study of Efficacy and Safety of Twice Daily Oral iptacopan in Adult PNH Patients who are naïve to complement inhibitor therapyEUCTR2020-003172-41-FRovartis Pharma AG40